Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.37 |
| ▸ | GUSB | P08236 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4448216 | 0.83 | CYP19A1 (0.61) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL9939642 | 0.82 | CYP19A1 (0.60) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL5493317 | 0.82 | CYP19A1 (0.60) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL29561383 | 0.80 | CYP19A1 (0.56) | CYP19A1CYP1B1CYP17A1MEN1LMNA | |
| SCHEMBL28263240 | 0.79 | CYP19A1 (0.61) | CYP19A1CYP1B1CYP17A1MEN1LMNA | |
| SCHEMBL606825 | 0.78 | CYP19A1 (0.67) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL32677703 | 0.78 | CYP19A1 (0.67) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL4885211 | 0.78 | CYP19A1 (0.67) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL26807214 | 0.78 | CYP19A1 (0.67) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL30881329 | 0.78 | CYP19A1 (0.57) | CYP19A1CYP1B1MEN1LMNASHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070077201-A1 | Stem cell expansion and uses | BIOVIE INC. | 2007-04-05 | — | — | US | claimed |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9115168-B2 | Steroids having 7-oxygen and 17-heteroaryl substitution-3 | NEURMEDIX, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9102702-B2 | Steroids having 7-oxygen and 17-heteroaryl substitution-2 | NEURMEDIX INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20140018337-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 | Harbor Therapeutics, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018336-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 | Harbor Therapeutics, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8569275-B2 | Steroids having 7-oxgen and 17-heteroaryl substitution | Harbor Therapeutics, Inc. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120029260-A1 | Screening and Treatment Method | BIOVIE INC. | 2012-02-02 | — | — | US | disclosed |
| US-20110212935-A1 | COMPOSITIONS AND TREATMENT METHODS-4 | HARBOR BIOSCIENCES, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7935839-B2 | Sepsis treatment methods | HARBOR BIOSCIENCES, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-1539183-A4 | THERAPEUTIC TREATMENT METHODS | HOLLIS EDEN PHARMACEUTICALS (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20070077203-A1 | Surrogate markers | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2007030124-A2 | TREATMENT SCREENING METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070053832-A1 | Drug product and process for making | BIOVIE INC. | 2007-03-08 | — | — | US | disclosed |
| US-20060088473-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-27 | — | — | US | disclosed |
| US-20060073099-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-06 | — | — | US | disclosed |
| EP-1539183-A1 | THERAPEUTIC TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050101581-A1 | Therapeutic treatment methods 2 | BIOVIE INC. | 2005-05-12 | — | — | US | disclosed |
| US-20040138187-A1 | Therapeutic treatment methods | BIOVIE INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004019953-A1 | THERAPEUTIC TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212935-A1 | COMPOSITIONS AND TREATMENT METHODS-4 | HSD3B1, HSD3B2, HSD17B13 | CYP19A1 46/4885CYP1B1 101/4885CYP17A1 14/4885 |
| US-20060088473-A1 | Treatment screening methods | HSD3B1, HSD3B2, HSD17B11 | CYP19A1 17/4885CYP1B1 261/4885CYP17A1 6/4885 |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HSD3B1, HSD3B2, HSD17B13 | CYP19A1 28/4885CYP1B1 80/4885CYP17A1 7/4885 |
| US-20070077203-A1 | Surrogate markers | TSG101, RAD50, DNASE1L3 | CYP19A1 1330/4885CYP1B1 2561/4885CYP17A1 2911/4885 |
| US-20140018336-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 | HSD3B1, HSD3B2, HSD17B13 | CYP19A1 33/4885CYP1B1 69/4885CYP17A1 8/4885 |
| US-20140018337-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 | HSD3B1, HSD3B2, HSD17B13 | CYP19A1 31/4885CYP1B1 71/4885CYP17A1 7/4885 |
| US-20060073099-A1 | Treatment screening methods | HSD17B11, HSD3B2, HSD3B1 | CYP19A1 6/4885CYP1B1 208/4885CYP17A1 7/4885 |
| US-20070053832-A1 | Drug product and process for making | CYP2D6, CYP3A5, CYP2B6 | CYP19A1 76/4885CYP1B1 31/4885CYP17A1 578/4885 |
| US-20050101581-A1 | Therapeutic treatment methods 2 | HSD3B2, HSD3B1, HSD17B2 | CYP19A1 58/4885CYP1B1 150/4885CYP17A1 14/4885 |
| US-20040138187-A1 | Therapeutic treatment methods | ELANE, ALOX15, IL15 | CYP19A1 71/4885CYP1B1 293/4885CYP17A1 19/4885 |
| US-20070077201-A1 | Stem cell expansion and uses | NES, CD44, FGF2 | CYP19A1 4139/4885CYP1B1 4754/4885CYP17A1 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.